Jan Beck

Mr. Beck currently serves as Chief Operating Officer of Mozart Therapeutics. He has over 20 years of leadership experience in business operations, corporate development, and finance from both biotech and large pharmaceutical companies. Most recently, Mr. Beck served as Head of R&D Operations at Lyell Immunopharma, where he directed R&D capital investments, infrastructure, and daily operations across the research sites in Washington and California. Prior to that, he was President & Site Head at Novo Nordisk Research, Inc. in Seattle. During his time at Novo Nordisk, Mr. Beck was responsible for the establishment, management, and operations of the Seattle site as well as supporting research hubs. He also headed the Global Business Intelligence unit at Novo Nordisk Corporate Finance in Denmark and held various international finance and operations roles in Copenhagen, Zürich, and Princeton, NJ.